Shin Seungwon, Park Soo Jung, Hwang Minwoo
National Agency for Development of Innovative Technologies in Korean Medicine, National Development Institute of Korean Medicine, Seoul, Republic of Korea.
Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea.
Integr Med Res. 2021 Jun;10(2):100664. doi: 10.1016/j.imr.2020.100664. Epub 2020 Sep 22.
(SJDBT, in Chinese) is a widely prescribed herbal medicine in traditional Korean medicine. This study aimed to evaluate the effectiveness and safety of SJDBT for treating chronic fatigue syndrome (CFS).
Ninety-six eligible participants were randomly allocated to either the SJDBT or placebo groups in a 1:1 ratio. Nine grams of SJDBT or placebo granules were administered to the patients for 8 weeks. The primary outcome was the response rate, defined as the proportion of participants with a score of 76 or higher in the Checklist Individual Strength assessment. Other measurements for fatigue severity, quality of life, and qi/blood/yin/yang deficiency were included. Safety was assessed throughout the trial.
At week 8, the response rate did not significantly differ between the groups (SJDBT: 35.4%; placebo: 54.2%; = 0.101, effect size [95% confidence interval] = 0.021 [-0.177, 0.218]). However, the scores of the visual analogue scale ( = 0.001, -0.327 [-0.506, -0.128]), Fatigue Severity Scale ( = 0.020, 0.480 [0.066, 0.889]), and Chalder fatigue scale ( = 0.004, -0.292 [-0.479, -0.101]) for the SJDBT group showed significant improvements in fatigue severity at the endpoint. Quality of life was not significantly different. Furthermore, SJDBT significantly ameliorated the severity of qi deficiency compared to that in the placebo group. No serious adverse events were observed.
This trial failed to show a significant improvement in fatigue severity, as assessed by the CIS-deprived response rate. It merely showed that SJDBT could alleviate the severity of fatigue and qi deficiency in patients with CFS. However, the further study is needed to confirm the details.
四君子汤(SJDBT,中文)是韩国传统医学中广泛使用的草药。本研究旨在评估四君子汤治疗慢性疲劳综合征(CFS)的有效性和安全性。
96名符合条件的参与者按1:1比例随机分配至四君子汤组或安慰剂组。给患者服用9克四君子汤或安慰剂颗粒,持续8周。主要结局是缓解率,定义为在个人力量清单评估中得分76分或更高的参与者比例。还包括疲劳严重程度、生活质量以及气血阴阳虚证的其他测量指标。在整个试验过程中评估安全性。
在第8周时,两组之间的缓解率无显著差异(四君子汤组:35.4%;安慰剂组:54.2%;P = 0.101,效应量[95%置信区间]= 0.021[-0.177, 0.218])。然而,四君子汤组的视觉模拟量表得分(P = 0.001,-0.327[-0.506, -0.128])、疲劳严重程度量表得分(P = 0.020,0.480[0.066, 0.889])和查尔德疲劳量表得分(P = 0.004,-0.292[-0.479, -0.101])在终点时显示疲劳严重程度有显著改善。生活质量无显著差异。此外,与安慰剂组相比,四君子汤显著改善了气虚的严重程度。未观察到严重不良事件。
本试验未能显示通过CIS剥夺缓解率评估的疲劳严重程度有显著改善。仅表明四君子汤可减轻CFS患者的疲劳严重程度和气虚。然而,需要进一步研究来证实细节。